No Data
No Data
The TOPIX 250 index of the Tokyo Stock Exchange rose for the third consecutive day, with strong demand for major stocks.
TOPIX Growth Market Index 812.45 +26.10 / volumne 0.2 billion 38.78 million shares / trading value 128.1 billion yen. TOPIX Growth Market 250 Index 634.78 +22.75 / volume 0.1 billion 64.43 million shares / trading value 97.7 billion yen. Today's growth market, the TOPIX Growth Market Index rose for the 10th consecutive day, and the TOPIX Growth Market 250 Index rose for the 3rd consecutive day. The number of rising stocks was 464, falling stocks were 93, unchanged stocks were 30. The US stock market continued to rise on the 19th. The Dow Jones Industrial Average was up 236.77 points.
Volume change rate ranking (9am) - RepliCel, Fujifilm Pharmaceuticals, etc. ranked in.
In the volume change rate ranking, by comparing the volume of the last 5 days with the volume on the delivery day, market participants can understand the trend of the market's interest. Top volume change rate [as of August 19, 9:32am] (compared to the average volume of the last 5 days): stock code, stock name, volume, 5-day average volume, volume change rate, and stock price change rate. <2389> Digital HD, 377200, 107185.08, 241.5%, 0% <488>
MDNT - Recognition of non-operating income
On the 9th, Medinet <2370> announced the recording of non-operating income for the cumulative period of the third quarter of the fiscal year 2024 (October 1, 2023 to June 30, 2024). In the cumulative period of the second quarter (October 1, 2023 to March 31, 2024), the investment business association achieved good results, and a profit of 0.02 billion yen was recorded from the investment business association, and 0.14 billion yen is expected to be recorded during the third quarter accounting period (April 1, 2024 to June 30, 2024).
Medinet has started manufacturing a new specific cell processed product called "S-DSC(R)" for hair regeneration.
On the 8th, Medinet announced that it will begin manufacturing specific cell processed products used in the treatment of male and female hair loss using cultured autologous hair follicle dermal sheath cells (DSC) outsourcing. This treatment involves taking DSC cells from the scalp of the occipital area that has not experienced hair loss, amplifying these cells in vitro, and administering the resulting specific cell processed product (S-DSC(R)) to the hair loss area. In recent years, research for hair regeneration for the purpose of treating hair loss has been progressing, but it takes time for hair to grow.
Medinet-- 3Q also had double-digit revenue growth, and cell processing sales revenue is progressing smoothly.
Medinet <2370> announced its third quarter results for the fiscal year ending September 2024 (October 2023-June 2024) on the 9th. Revenue increased by 19.8% YoY to ¥0.589 billion, operating loss was ¥0.996 billion (compared to a loss of ¥1.046 billion in the same period last year), ordinary loss was ¥0.948 billion (compared to a loss of ¥1.043 billion in the same period last year), and net loss for the quarter was ¥0.951 billion (compared to a loss of ¥1.045 billion in the same period last year). Sales of the cell processing industry increased by 19.9% YoY to ¥0.589 billion, driven by the expansion of cell processing outsourcing.
MEDINET Co. Sees Sales Rise Amidst Losses
No Data